170 related articles for article (PubMed ID: 26913384)
21. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
23. [Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance].
Han X; Deng ZK; Zhang CW; Yu L; Liu XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1714-1718. PubMed ID: 34893099
[TBL] [Abstract][Full Text] [Related]
24. [Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R].
Dai Q; Ge YQ
Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(2):385-389. PubMed ID: 29552859
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
27. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Zhang K; Xu J; Huang X; Wu L; Wen C; Hu Y; Su Y; Chen Y; Zhang Z
Cancer Chemother Pharmacol; 2007 Sep; 60(4):581-7. PubMed ID: 17435997
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo.
Chun-Guang W; Jun-Qing Y; Bei-Zhong L; Dan-Ting J; Chong W; Liang Z; Dan Z; Yan W
Eur J Pharmacol; 2010 Feb; 627(1-3):33-41. PubMed ID: 19857484
[TBL] [Abstract][Full Text] [Related]
29. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
30. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells.
Zhang KZ; Xu JH; Huang XW; Wu LX; Su Y; Chen YZ
Acta Pharmacol Sin; 2007 Jan; 28(1):105-10. PubMed ID: 17184589
[TBL] [Abstract][Full Text] [Related]
31. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
32. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
[TBL] [Abstract][Full Text] [Related]
33. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
34. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
35. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
36. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
37. Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Liu N; Li P; Zang S; Liu Q; Ma D; Sun X; Ji C
PLoS One; 2015; 10(2):e0116880. PubMed ID: 25647305
[TBL] [Abstract][Full Text] [Related]
38. Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/β‑catenin pathway.
Ma W; Liu F; Yuan L; Zhao C; Chen C
Oncol Rep; 2020 Jan; 43(1):260-269. PubMed ID: 31746437
[TBL] [Abstract][Full Text] [Related]
39. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
40. [Synthesis of emodin derivatives and their inhibiting effects on proliferation of leukemia cell lines].
Zheng JT; Wang WF; Li J; Zheng ZH; Liu TB; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):53-6. PubMed ID: 23484691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
